What Has Been the Growth of the Trulicity Market So Far?
The trulicity market has seen considerable growth due to a variety of factors.
• The market size for Trulicity has been experiencing robust growth in the past few years. It is expected to expand from $7,320 million in 2024 to $7,980 million in 2025, displaying a compound annual growth rate (CAGR) of 9%.
This growth during the historic period is due to numerous factors including the increasing incidence of obesity, rise in the diabetic population, expansion of the pharmaceutical sector, increasing unhealthy lifestyles, proven effectiveness of various therapies, and a rise in healthcare spending.
How Will the Trulicity Market?
The trulicity market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of Trulicity is projected to experience substantial growth in the upcoming years, reaching $11,180 million in 2029 with a compound annual growth rate (CAGR) of 8.8%.
A few factors driving this trend in the forecast period include the growing acceptance of digital health technologies, heightened health consciousness among individuals, the expansion of educational and awareness programs, the rise in demand for innovative treatments, and increased accessibility to healthcare activities. Some of the significant trends during this period are the integration of technology, strategic partnerships, product innovation, a focus on personalized health solutions, combination therapies, and sustainable initiatives.
Which Factors Are Boosting Growth In The Trulicity Market?
The escalation in the number of diabetes patients is projected to spur the growth of the trulicity market. Characterized by high blood sugar levels due to the body's inability to efficiently produce or use insulin, diabetes is a long-term health issue that can pose severe complications if not properly managed. The escalating number of diabetic individuals is mainly due to urbanization, poor dietary habits, lack of physical activity, and genetic susceptibility. This rise in the number of diabetes patients increases the need for effective treatments such as trulicity, which aids in the regulation of blood glucose levels and enhances patient outcomes. For instance, data from the Office for Health Improvement and Disparities, a government department in the UK, revealed that the proportion of individuals with type 1 diabetes in England who received 8 care processes at GP practices participating in the NDA had increased to 43.8% in March 2024, a climb from 35.2% in 2022. Therefore, the increasing number of diabetes patients is contributing to the expansion of the trulicity market.
What Key Areas Define The Segmentation Of The Global Trulicity Market?
The trulicity market covered in this report is segmented –
1) By Type: Prefilled Syringe Package, Vial Package
2) By Application: Type 2 Diabetes Management, Glycemic Control, Weight Management, Cardiovascular Risk Reduction
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Pre-Book The Trulicity Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Trulicity Market?
Trend 1.
The Trulicity market is trending towards the development of innovative Trulicity (dulaglutide) drugs in order to decrease the probability of significant adverse cardiovascular incidents. Trulicity, a once-weekly injectable, is engineered to improve blood glucose regulation in type 2 diabetes patients, mimicking the GLP-1 hormone to boost insulin secretion, delay gastric emptying, and decrease hunger. In November 2022, the US Food and Drug Administration (FDA) gave clearance to Eli Lilly and Company, a U.S. pharmaceutical firm, to utilize Trulicity (dulaglutide) as a supplement to diet and exercise to enhance blood glucose control in adults and children aged 10 and above with type 2 diabetes after a 26-week double-blind, placebo-controlled trial with an additional 26-week open-label extension, which included 154 pediatric patients aged 10 and above suffering from Type 2 Diabetes Mellitus (T2DM).
Emphasizing on Strategic Investments to Satisfy Rising Demand in the Trulicity Market
A dominant trend found in the Trulicity market is incorporating strategic investment approaches such as the construction of biologics production facilities to attain a competitive edge and to satisfy the increasing demand. Biologics production facilities are specialized manufacturing plants purpose-built to form biologic drugs, sophisticated therapies originating from living organisms like monoclonal antibodies, vaccines, and cellular and gene therapies. For example, in January 2023, Eli Lilly and Company, a U.S. pharmaceutical firm, devoted $450 million to enlarge its production plant in North Carolina, stimulating the production of diabetes drug, Trulicity. This additional investment of $1.7 billion in the facility is set to begin production later within the year, with full operation by 2027, creating an extra 100 jobs. Furthermore, Lilly is currently developing two new facilities in Indiana and investing €400 million in biologics production in Ireland. The company's future plans consist of spending $2.5 billion on manufacturing capacity to address the rising demand and the launch of new products.
Who Are the Key Players In The Trulicity Market?
Major companies operating in the trulicity market include:
• Eli Lilly And Company
• Novo Nordisk
What Is The Most Dominant Region In The Trulicity Market?
North America was the largest region in the trulicity market in 2024. The regions covered in the trulicity market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
